Difference between revisions of "FDG-PET Biomarker Ctte"

From QIBA Wiki
Jump to: navigation, search
(Subcommittee Status, Goals & Needed Resources)
Line 1: Line 1:
== [[FDG-PET/CT Technical Committee Page]] ==
+
== Quantitative FDG-PET Technical Committee Mission ==
  
'''Mission; Foster adoption of ...'''
+
*'''Mission; Foster adoption of ...'''
*pragmatic and cost effective standards for
+
**pragmatic and cost effective standards for
*accurate and reproducible
+
**accurate and reproducible
*longitudinal
+
**longitudinal
*quantitation of
+
**quantitation of
*biologic parameters
+
**biologic parameters
*with clinical relevance
+
**with clinical relevance
*and known sigma
+
**and known sigma
  
==SubCommittees==
+
*[[Media:Why_QIBA_PET-CT_specifics.pdf|"Why QIBA?" - Specifics associated with PET-CT device and software manufacturers.]]
 +
 
 +
==Meetings / Call Summaries==
 +
*[[Monthly FDG-PET Call Summaries]]
 +
 
 +
==Profile Development==
 +
Drafting:
 +
* [[Media: Profile_qFDG-PET_01312011.doc|Whole Body FDG-PET]] ''Word version of Profile applicable to multiple indications, 01-31-2011''
 +
Archive:
 +
* [[Profile: FDG-PET Whole Body]] ''First version of Profile, 2009 (currently inactive)''
 +
 
 +
==Working Documents and Reference Materials==
 
*[[Covariates Rationale]]
 
*[[Covariates Rationale]]
 
*[[Standardized Uptake Value (SUV)]]
 
*[[Standardized Uptake Value (SUV)]]
Line 17: Line 28:
 
*[[Software Version Tracking]]
 
*[[Software Version Tracking]]
  
==Profiling Activities==
+
*[[Media:PET-CovariatesRationale YAP 20090310.ppt|Covariates Rationale SubCtte]] ''March 2009''
Write Profile documents to which equipment and sites can conform to accomplish Quantification goals.
+
*[[Media:PET-DRO KINAHAN 2009-03-10.ppt|Digital Reference Objects SubCtte]] ''March 2009''
 
+
*[[Media:PET-QualityControlMetrics YAP 20090224.ppt|Quality Control Metrics SubCtte]] ''March 2009''
* [[What Are Profiles?]]
+
*[[Media:PET-ROI-Definitions TURKINGTON 20090306.ppt|Region of Interest SubCtte]] ''March 2009''
* [[Profile: FDG-PET Whole Body]]
+
*[[Media:PET-SoftwareVersionTracking SHAO 3-13-09-2.ppt|Software Version Tracking SubCtte]] ''March 2009''
 
+
==Reference Materials==
+
  
 
*[[Media:Boellaard-Aanbevelingen NEDPAS 2007 - EN- 17032009.pdf|NL Standardization Protocol for Quantitative FDG-PET in multi-Center Trials - Dr Ronald Boellaard]]
 
*[[Media:Boellaard-Aanbevelingen NEDPAS 2007 - EN- 17032009.pdf|NL Standardization Protocol for Quantitative FDG-PET in multi-Center Trials - Dr Ronald Boellaard]]
Line 31: Line 40:
 
Please keep the following in mind:
 
Please keep the following in mind:
  
The development of this protocol was started about 4 years ago (2005) and approved more than 1 year ago in The Netherlands (NL). However, with gained insight, changes are scheduled to be incorporated in the next version by 2010. The following changes will be made (consider them being applied already or underway):
+
The development of this protocol was started about 2005 and approved more than 1 year ago in The Netherlands (NL). However, with gained insight, changes are scheduled to be incorporated in the next version by 2010. The following changes will be made (consider them being applied already or underway):
  
 
*Use of oral contrast is now excluded but will be allowed in the next version
 
*Use of oral contrast is now excluded but will be allowed in the next version
Line 62: Line 71:
 
*[[Media:ProfilingSlides-ABuckler-20090331.pdf|QIBA Profiling Process-03.31.2009 (Andrew Buckler, MS)]]
 
*[[Media:ProfilingSlides-ABuckler-20090331.pdf|QIBA Profiling Process-03.31.2009 (Andrew Buckler, MS)]]
 
*[[Media:Frank-FDG-PET-20090520.ppt|FDG-PET/CT Technical Committee summary 2009.05.20 Richard Frank]]
 
*[[Media:Frank-FDG-PET-20090520.ppt|FDG-PET/CT Technical Committee summary 2009.05.20 Richard Frank]]
 
==Subcommittee Status, Goals & Resources Needed==
 
 
*[[Media:PET-CovariatesRationale YAP 20090310.ppt|Covariates Rationale SubCtte]] ''March 2009''
 
*[[Media:PET-DRO KINAHAN 2009-03-10.ppt|Digital Reference Objects SubCtte]] ''March 2009''
 
*[[Media:PET-QualityControlMetrics YAP 20090224.ppt|Quality Control Metrics SubCtte]] ''March 2009''
 
*[[Media:PET-ROI-Definitions TURKINGTON 20090306.ppt|Region of Interest SubCtte]] ''March 2009''
 
*[[Media:PET-SoftwareVersionTracking SHAO 3-13-09-2.ppt|Software Version Tracking SubCtte]] ''March 2009''
 
 
==Call Summaries==
 
*[[Monthly FDG-PET Call Summaries]]
 

Revision as of 00:07, 16 February 2011

Quantitative FDG-PET Technical Committee Mission

  • Mission; Foster adoption of ...
    • pragmatic and cost effective standards for
    • accurate and reproducible
    • longitudinal
    • quantitation of
    • biologic parameters
    • with clinical relevance
    • and known sigma

Meetings / Call Summaries

Profile Development

Drafting:

  • Whole Body FDG-PET Word version of Profile applicable to multiple indications, 01-31-2011

Archive:

Working Documents and Reference Materials

The Netherlands Standardization Protocol for Quantitative FDG-PET in Multi-center Trials (English translation of Version 1)

Please keep the following in mind:

The development of this protocol was started about 2005 and approved more than 1 year ago in The Netherlands (NL). However, with gained insight, changes are scheduled to be incorporated in the next version by 2010. The following changes will be made (consider them being applied already or underway):

  • Use of oral contrast is now excluded but will be allowed in the next version
  • We are currently working on standards for CT as well, including GL for doing CT-QC (in cooperation with the radiologists/radiology societies in NL)
  • There will be an upper limit for dosage
  • We are working on traceable/calibrated and mutually linked sources for both PET and the dose calibrator and these will be used for absolute (rather than cross-) calibration (but in addition to the cross-calibration using FDG).
  • Reconstruction settings given in the protocol are indicative and are likely not applicable for future scanners and software upgrades. Therefore reconstruction parameters should be set such that they provide results that meet the specifications given for the multi-center QC experiments. Same settings should then be applied to patient studies (see also comments under "execptions/special features” and comments made in the paper by Boellaard et al. EJNMMI 2008).
  • Various other minor edits/typos/changes

The protocol is not a step-by-step description of the logistics for doing a PET/CT study. However, it has been set up in a somewhat chronological order and may thus be used to populate (copy-paste) such a step-by-step description. Additional work required ... FDG-PET/CT Technical Committee input is highly appreciated.

Submitted by Ronald Boellaard, PhD

Submitted by Richard L. Wahl, MD and Martin A. Lodge, PhD

Submitted by Eric S. Perlman, MD

Slide Presentations